SCYNEXIS, Inc.
SCYXHealthcareNASDAQDrug Manufacturers - Specialty & Generic · Last scanned May 30, 2026
Scan Results
Daily timeframeSCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. At a $56.0M market cap, SCYNEXIS, Inc. ranks as a micro-cap company within healthcare. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence.
Market Cap
$56.0M
Beta
—
P/E (TTM)
—
P/E (Fwd)
-2.24
EPS (TTM)
$-3.84
EPS (Fwd)
$-0.32
ROE
-53.4%
ROA
-21.0%
Cash
$59.3M
Total Debt
$2.1M
Free CF
$2.7M
52W Change
-20.8%
Annual Financials
Cash vs Debt
SCYNEXIS, Inc. holds $59.3M in cash against $2.1M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow comes in at $2.7M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at -53.4%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $5.1M (2022) to $20.6M (2025), reflecting a 305% increase over the period.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence SCYNEXIS, Inc.'s trajectory.